Rational Approaches to the Design of Therapeutics Targeting Molecular Markers: The Case of Chronic Myelogenous Leukemia

@article{Saglio2004RationalAT,
  title={Rational Approaches to the Design of Therapeutics Targeting Molecular Markers: The Case of Chronic Myelogenous Leukemia},
  author={G. Saglio and A. Morotti and G. Mattioli and E. Messa and E. Giugliano and G. Volpe and G. Rege-Cambrin and D. Cilloni},
  journal={Annals of the New York Academy of Sciences},
  year={2004},
  volume={1028}
}
  • G. Saglio, A. Morotti, +5 authors D. Cilloni
  • Published 2004
  • Biology, Medicine
  • Annals of the New York Academy of Sciences
  • Abstract: Progress in understanding the molecular basis of signal transmission and transduction has contributed substantially to clarifying the mechanisms of leukemogenesis and of leukemia progression and has led to the identification of a number of specific molecular targets for treatment. Chronic myeloid leukemia (CML) has provided one of the best models, as the identification of a leukemia‐specific hybrid tyrosine kinase (BCR‐ABL, p210, p190) has led to the identification and the successful… CONTINUE READING
    26 Citations
    Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
    • 3
    • PDF
    Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
    • 6
    • PDF
    BLCTT_A_228815 45..52
    Cytogenetic investigation in chronic myeloid leukemia: study from an Indian population.
    • 14
    Potential use of nucleic acid-based agents in the sensitization of nasopharyngeal carcinoma to radiotherapy.
    • 21

    References

    SHOWING 1-10 OF 45 REFERENCES
    Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    • 4,763
    • PDF
    The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
    • 185
    • PDF